Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma.

PMID: 20479282
Journal: BLOOD
Year: 2010
Reference: Blood. 2010 Aug 26;116(8):e12-7. Epub 2010 May 17.
Impact factor: 10.555
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1182/blood-2010-02-270009

A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma.

PMID: 20479282
Journal: BLOOD
Year: 2010
Reference: Blood. 2010 Aug 26;116(8):e12-7. Epub 2010 May 17.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1182/blood-2010-02-270009

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

PMID: 20110292
Journal: ANNALS OF ONCOLOGY
Year: 2010
Reference: Ann Oncol. 2010 Feb;21(2):217-22.
Impact factor: 5.647
Publication type: Paper in international publication
Authors: Baselga, J, Tan, E-H, Ramlau, R, Pluzanska, A, Kuo, H-P, Reck, M, Milanowski, J, Felip, E, Yang, P-C, Damyanov, D et al.
DOI: 10.1093/annonc/mdp520

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

PMID: 20110292
Journal: ANNALS OF ONCOLOGY
Year: 2010
Reference: Ann Oncol. 2010 Feb;21(2):217-22.
Impact factor:
Publication type: Paper in international publication
Authors: Akimov, M; Au, J S-K; Baselga, J; Damyanov, D; Delmar, P; Essioux, L; Felip, E; Hillenbach, C; Klughammer, B; Kuo, H-P et al.
DOI: 10.1093/annonc/mdp520

A multi-centre study of efficacy and safety of Intratect((R)), a novel intravenous immunoglobulin preparation.

PMID: 20550545
Journal: CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Year: 2010
Reference: Clin Exp Immunol. 2010 Sep;161(3):512-7. doi: 10.1111/j.1365-2249.2010.04187.x.
Impact factor: 3.009
Publication type: Paper in international publication
Authors: , , , , , et al.
DOI: 10.1111/j.1365-2249.2010.04187.x

A multi-centre study of efficacy and safety of Intratect((R)), a novel intravenous immunoglobulin preparation.

PMID: 20550545
Journal: CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Year: 2010
Reference: Clin Exp Immunol. 2010 Sep;161(3):512-7. doi: 10.1111/j.1365-2249.2010.04187.x.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; et al.
DOI: 10.1111/j.1365-2249.2010.04187.x

A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis.

PMID: 20080591
Journal: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Year: 2010
Reference: Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1672-7. Epub 2010 Jan 8.
Impact factor: 9.432
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1073/pnas.0908359107

A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis.

PMID: 20080591
Journal: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Year: 2010
Reference: Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1672-7. Epub 2010 Jan 8.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1073/pnas.0908359107

A new application of Streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens.

PMID: 20619254
Journal: CLINICA CHIMICA ACTA
Year: 2010
Reference: Clin Chim Acta. 2010 Nov 11;411(21-22):1675-8. Epub 2010 Jul 6.
Impact factor: 2.535
Publication type: Paper in international publication
Authors: Rodrigo, Maria J, Postigo, Idoia, Wangensteen, Owen, Guisantes, Jorge A, Martinez, Jorge et al.
DOI: 10.1016/j.cca.2010.06.031

A new application of Streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens.

PMID: 20619254
Journal: CLINICA CHIMICA ACTA
Year: 2010
Reference: Clin Chim Acta. 2010 Nov 11;411(21-22):1675-8. Epub 2010 Jul 6.
Impact factor:
Publication type: Paper in international publication
Authors: Guisantes, Jorge A; Martinez, Jorge; Postigo, Idoia; Rodrigo, Maria J; Wangensteen, Owen et al.
DOI: 10.1016/j.cca.2010.06.031

A new culture technique that allows in vitro meiotic prophase development of fetal human oocytes.

PMID: 19828555
Journal: HUMAN REPRODUCTION
Year: 2010
Reference: Hum Reprod. 2010 Jan;25(1):74-84. Epub 2009 Oct 14.
Impact factor: 3.859
Publication type: Paper in international publication
Authors: Brieno-Enriquez, M A, Robles, P, Garcia-Cruz, R, Roig, I, Cabero, L, Martinez, F, Garcia Caldes, M et al.
DOI: 10.1093/humrep/dep351

A new culture technique that allows in vitro meiotic prophase development of fetal human oocytes.

PMID: 19828555
Journal: HUMAN REPRODUCTION
Year: 2010
Reference: Hum Reprod. 2010 Jan;25(1):74-84. Epub 2009 Oct 14.
Impact factor:
Publication type: Paper in international publication
Authors: Brieno-Enriquez, M A; Cabero, L; Garcia Caldes, M; Garcia-Cruz, R; Martinez, F; Robles, P; Roig, I et al.
DOI: 10.1093/humrep/dep351

A new generation of proto-oncogenes: Cold-inducible RNA binding proteins.

PMID: 19900510
Journal: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Year: 2010
Reference: Biochim Biophys Acta. 2010 Jan;1805(1):43-52. Epub 2009 Nov 10.
Impact factor: 11.685
Publication type: Review in international publication
Authors: et al.
DOI: 10.1016/j.bbcan.2009.11.001

A new generation of proto-oncogenes: Cold-inducible RNA binding proteins.

PMID: 19900510
Journal: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Year: 2010
Reference: Biochim Biophys Acta. 2010 Jan;1805(1):43-52. Epub 2009 Nov 10.
Impact factor:
Publication type: Review in international publication
Authors: et al.
DOI: 10.1016/j.bbcan.2009.11.001

A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.

PMID: 19649703
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2010
Reference: Breast Cancer Res Treat. 2010 May;121(1):221-5. Epub 2009 Aug 1.
Impact factor: 4.696
Publication type: Paper in international publication
Authors: Diez, Orland, Gutierrez-Enriquez, Sara, Mediano, Carmen, Masas, Miriam, Saura, Cristina, Gadea, Neus, Balmana, Judith et al.
DOI: 10.1007/s10549-009-0494-y

A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.

PMID: 19649703
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2010
Reference: Breast Cancer Res Treat. 2010 May;121(1):221-5. Epub 2009 Aug 1.
Impact factor:
Publication type: Paper in international publication
Authors: Balmana, Judith; Diez, Orland; Gadea, Neus; Gutierrez-Enriquez, Sara; Masas, Miriam; Mediano, Carmen; Saura, Cristina et al.
DOI: 10.1007/s10549-009-0494-y

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

PMID: 20615828
Journal: Clinical & Translational Oncology
Year: 2010
Reference: Clin Transl Oncol. 2010 Jul;12(7):503-8.
Impact factor: 1.146
Publication type: Paper in international publication
Authors: Bellmunt, Joaquim, Maroto-Rey, Pablo, Trigo, Jose M, Carles, Joan, Guillem, Vicente, Lopez-Martin, Jose A, Anton-Torres, Antonio, Urruticoechea, Leyrer et al.
DOI:

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

PMID: 20615828
Journal: Clinical & Translational Oncology
Year: 2010
Reference: Clin Transl Oncol. 2010 Jul;12(7):503-8.
Impact factor:
Publication type: Paper in international publication
Authors: Anton-Torres, Antonio; Bellmunt, Joaquim; Carles, Joan; Guillem, Vicente; Lopez-Martin, Jose A; Maroto-Rey, Pablo; Trigo, Jose M; Urruticoechea, Leyrer et al.
DOI:

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

PMID: 20459775
Journal: BMC CANCER
Year: 2010
Reference: BMC Cancer. 2010 May 11;10(1):190.
Impact factor: 2.736
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1186/1471-2407-10-190

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

PMID: 20459775
Journal: BMC CANCER
Year: 2010
Reference: BMC Cancer. 2010 May 11;10(1):190.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1186/1471-2407-10-190

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.

PMID: 20542806
Journal: EuroIntervention
Year: 2010
Reference: EuroIntervention. 2010 May;6(1):112-6. doi: 10.4244/.
Impact factor:
Publication type: Letter or abstract
Authors: Moreno, Raul, Garcia, Eulogio, Teles, Rui C, Almeida, Manuel S, Carvalho, Henrique Cyrne, Sabate, Manel, Martin-Reyes, Roberto, Rumoroso, Jose Ramon, Galeote, Guillermo, Goicolea, Francisco Javier et al.
DOI: 10.4244/

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.

PMID: 20542806
Journal: EuroIntervention
Year: 2010
Reference: EuroIntervention. 2010 May;6(1):112-6. doi: 10.4244/EIJV6I1A17
Impact factor:
Publication type: Paper in international publication
Authors: Almeida, Manuel S; Calvo, Luis; Carvalho, Henrique Cyrne; Ferreira, Rui; Galeote, Guillermo; Garcia, Eulogio; Goicolea, Francisco Javier; Jimenez-Valero, Santiago; Lopez de Sa, Esteban; Lopez-Sendon, Jose-Luis et al.
DOI: 10.4244/EIJV6I1A17

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

PMID: 20431381
Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL
Year: 2010
Reference: Pediatr Infect Dis J. 2010 May;29(5):415-20.
Impact factor: 2.854
Publication type: Paper in international publication
Authors: Castel Sanchez, P, Garcia Miguel, P, Madero-Lopez, L, Sanchez de Toledo, J, Flynn, P, Green, M, Jafri, H, Nania, J, Pulsipher, M, Reilly, A et al.
DOI: 10.1097/INF.0b013e3181da2171

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

PMID: 20431381
Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL
Year: 2010
Reference: Pediatr Infect Dis J. 2010 May;29(5):415-20.
Impact factor:
Publication type: Paper in international publication
Authors: Arndt, Carola A S; Arndt, Carola A S; Berthold, F; Bourque, Michael R; Castel Sanchez, P; Chow, Joseph W; de Pauw, Ben E; DePauw, Ben E; Flynn, P; Garcia Miguel, P et al.
DOI: 10.1097/INF.0b013e3181da2171

Publications

Publications searcher

A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma.

A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma.

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

A multi-centre study of efficacy and safety of Intratect((R)), a novel intravenous immunoglobulin preparation.

A multi-centre study of efficacy and safety of Intratect((R)), a novel intravenous immunoglobulin preparation.

A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis.

A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis.

A new application of Streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens.

A new application of Streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens.

A new culture technique that allows in vitro meiotic prophase development of fetal human oocytes.

A new culture technique that allows in vitro meiotic prophase development of fetal human oocytes.

A new generation of proto-oncogenes: Cold-inducible RNA binding proteins.

A new generation of proto-oncogenes: Cold-inducible RNA binding proteins.

A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.

A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

Patronage:

Collaborating:

Accreditations: